Literature DB >> 30153083

A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture.

Chunlei Wang1, Bhargavi Vemulapalli1, Mingyan Cao1, Dhanesh Gadre2, Jihong Wang1, Alan Hunter2, Xiangyang Wang1, Dengfeng Liu1.   

Abstract

Immunoglobulin G-like bispecific antibodies with asymmetric architecture are among the most widely used bispecific antibody formats for diagnostic and therapeutic applications. The primary technical challenge for this format is how to achieve correctly paired assembly of four unique polypeptide chains. Advances in protein engineering and process development are being used to overcome these challenges and are driving a corresponding demand for sensitive analytical tools to monitor and control mispaired species. Here, we report a systematic approach for analysis and characterization of mispairing in asymmetric bispecific antibodies. This approach consists of three orthogonal components, the first of which is a liquid chromatography (LC)-mass spectrometry (MS)-based method to measure the mass of intact antibodies. This method is used for fast analysis of mispairing and requires minimal method development, which makes it an ideal choice for early-stage development. The second component is a hydrophobic interaction chromatography (HIC)-based mispairing method that is suitable for lot release testing. The HIC method is robust and quality control friendly, and offers great linearity, precision, and accuracy. The third component is a two-dimensional LC-MS method for on-line chromatographic peak identification, which not only expedites this task but also reduces the risk of undesirable modifications during conventional fraction collection. These three methods dovetail to form the foundation of a complementary toolbox for analysis and characterization of mispairing in asymmetric bispecific antibodies and provide guidance and support for process development throughout the drug development life cycle.

Entities:  

Keywords:  Bispecific antibody; DuetMab; hydrophobic interaction chromatography; mispairing; two-dimensional liquid chromatography

Mesh:

Substances:

Year:  2018        PMID: 30153083      PMCID: PMC6284573          DOI: 10.1080/19420862.2018.1511198

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  33 in total

Review 1.  Bispecific antibodies.

Authors:  Roland E Kontermann; Ulrich Brinkmann
Journal:  Drug Discov Today       Date:  2015-02-26       Impact factor: 7.851

2.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

Authors:  J B Ridgway; L G Presta; P Carter
Journal:  Protein Eng       Date:  1996-07

3.  An efficient route to human bispecific IgG.

Authors:  A M Merchant; Z Zhu; J Q Yuan; A Goddard; C W Adams; L G Presta; P Carter
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

4.  Analysis and purification of IgG4 bispecific antibodies by a mixed-mode chromatography.

Authors:  Xiaoyu Yang; Ying Zhang; Fengqiang Wang; Larry Jin Wang; Daisy Richardson; Mohammed Shameem; Alexandre Ambrogelly
Journal:  Anal Biochem       Date:  2015-06-16       Impact factor: 3.365

5.  Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Authors:  Rebecca Croasdale; Katharina Wartha; Juergen M Schanzer; Klaus-Peter Kuenkele; Carola Ries; Klaus Mayer; Christian Gassner; Martina Wagner; Nikolaos Dimoudis; Sylvia Herter; Christiane Jaeger; Claudia Ferrara; Eike Hoffmann; Lothar Kling; Wilma Lau; Roland F Staack; Julia Heinrich; Werner Scheuer; Jan Stracke; Christian Gerdes; Ulrich Brinkmann; Pablo Umana; Christian Klein
Journal:  Arch Biochem Biophys       Date:  2012-03-21       Impact factor: 4.013

6.  Structural and functional characterization of the trifunctional antibody catumaxomab.

Authors:  Dirk Chelius; Peter Ruf; Patrick Gruber; Matthias Plöscher; Reinhard Liedtke; Eva Gansberger; Juergen Hess; Michael Wasiliu; Horst Lindhofer
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 7.  Blinatumomab: a historical perspective.

Authors:  Dirk Nagorsen; Peter Kufer; Patrick A Baeuerle; Ralf Bargou
Journal:  Pharmacol Ther       Date:  2012-08-24       Impact factor: 12.310

8.  Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.

Authors:  Nicolas Fischer; Greg Elson; Giovanni Magistrelli; Elie Dheilly; Nicolas Fouque; Amélie Laurendon; Franck Gueneau; Ulla Ravn; Jean-François Depoisier; Valery Moine; Sylvain Raimondi; Pauline Malinge; Laura Di Grazia; François Rousseau; Yves Poitevin; Sébastien Calloud; Pierre-Alexis Cayatte; Mathias Alcoz; Guillemette Pontini; Séverine Fagète; Lucile Broyer; Marie Corbier; Delphine Schrag; Gérard Didelot; Nicolas Bosson; Nessie Costes; Laura Cons; Vanessa Buatois; Zoe Johnson; Walter Ferlin; Krzysztof Masternak; Marie Kosco-Vilbois
Journal:  Nat Commun       Date:  2015-02-12       Impact factor: 14.919

9.  Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.

Authors:  Whitney Shatz; Shan Chung; Bing Li; Brett Marshall; Max Tejada; Wilson Phung; Wendy Sandoval; Robert F Kelley; Justin M Scheer
Journal:  MAbs       Date:  2013-08-29       Impact factor: 5.857

10.  Improving target cell specificity using a novel monovalent bispecific IgG design.

Authors:  Yariv Mazor; Vaheh Oganesyan; Chunning Yang; Anna Hansen; Jihong Wang; Hongji Liu; Kris Sachsenmeier; Marcia Carlson; Dhanesh V Gadre; Martin Jack Borrok; Xiang-Qing Yu; William Dall'Acqua; Herren Wu; Partha Sarathi Chowdhury
Journal:  MAbs       Date:  2015       Impact factor: 5.857

View more
  2 in total

Review 1.  Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates.

Authors:  Xiaoyu Zhu; Shihan Huo; Chao Xue; Bo An; Jun Qu
Journal:  J Pharm Anal       Date:  2020-05-23

2.  The eIg technology to generate Ig-like bispecific antibodies.

Authors:  Lennart Kühl; Nadine Aschmoneit; Roland E Kontermann; Oliver Seifert
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.